BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26425463)

  • 1. Pleiotropic effects of statins.
    Kavalipati N; Shah J; Ramakrishan A; Vasnawala H
    Indian J Endocrinol Metab; 2015; 19(5):554-62. PubMed ID: 26425463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Timely Top Med Cardiovasc Dis; 2007 Apr; 11():E10. PubMed ID: 17473899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation.
    Arnaud C; Mach F
    Arch Mal Coeur Vaiss; 2005 Jun; 98(6):661-6. PubMed ID: 16007821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia.
    Oesterle A; Liao JK
    Curr Vasc Pharmacol; 2019; 17(3):222-232. PubMed ID: 30124154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.
    Arnaud C; Veillard NR; Mach F
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Apr; 5(2):127-34. PubMed ID: 15853754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.
    Wang CY; Liu PY; Liao JK
    Trends Mol Med; 2008 Jan; 14(1):37-44. PubMed ID: 18068482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
    Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
    Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
    Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J
    Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
    Kumai T; Matsumoto N; Koitabashi Y; Takeba Y; Oonuma S; Sekine S; Tadokoro M; Kobayashi S
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jul; 3(3):195-201. PubMed ID: 15974884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
    Takemoto M; Liao JK
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1712-9. PubMed ID: 11701455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.
    Liao JK
    Am J Cardiol; 2005 Sep; 96(5A):24F-33F. PubMed ID: 16126020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins and cancer.
    Vallianou NG; Kostantinou A; Kougias M; Kazazis C
    Anticancer Agents Med Chem; 2014 Jun; 14(5):706-12. PubMed ID: 24295174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects of HMG-CoA reductase inhibitors.
    Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
    Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
    Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
    Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis.
    Campia I; Lussiana C; Pescarmona G; Ghigo D; Bosia A; Riganti C
    Br J Pharmacol; 2009 Dec; 158(7):1777-86. PubMed ID: 19888963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mevalonate-suppressive dietary isoprenoids for bone health.
    Mo H; Yeganehjoo H; Shah A; Mo WK; Soelaiman IN; Shen CL
    J Nutr Biochem; 2012 Dec; 23(12):1543-51. PubMed ID: 22981371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct vascular effects of HMG-CoA reductase inhibitors.
    Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
    Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of COX-2 expression by statins in human monocytic cells.
    Habib A; Shamseddeen I; Nasrallah MS; Antoun TA; Nemer G; Bertoglio J; Badreddine R; Badr KF
    FASEB J; 2007 Jun; 21(8):1665-74. PubMed ID: 17317725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.